Monitoring LXRX open interest helps you see where real money is positioned on Lexicon Pharmaceuticals Inc's options and which strikes are attracting the most commitment from traders. Lexicon Pharmaceuticals Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor LXRX options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising LXRX options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Lexicon Pharmaceuticals Inc to settle.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where LXRX open interest is concentrated. Our scanner maps Lexicon Pharmaceuticals Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Lexicon Pharmaceuticals Inc's options open interest as the signal it is, not as an afterthought.
